AU2531295A - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- AU2531295A AU2531295A AU25312/95A AU2531295A AU2531295A AU 2531295 A AU2531295 A AU 2531295A AU 25312/95 A AU25312/95 A AU 25312/95A AU 2531295 A AU2531295 A AU 2531295A AU 2531295 A AU2531295 A AU 2531295A
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA94/3740 | 1994-05-27 | ||
ZA943740 | 1994-05-27 | ||
PCT/GB1995/001152 WO1995032737A1 (en) | 1994-05-27 | 1995-05-22 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2531295A true AU2531295A (en) | 1995-12-21 |
Family
ID=25583939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU25312/95A Abandoned AU2531295A (en) | 1994-05-27 | 1995-05-22 | Pharmaceutical composition |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0760680A1 (en) |
JP (1) | JPH10500982A (en) |
AU (1) | AU2531295A (en) |
BR (1) | BR9507768A (en) |
CA (1) | CA2190598A1 (en) |
WO (1) | WO1995032737A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA959469B (en) * | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
IT1283029B1 (en) * | 1996-05-17 | 1998-04-03 | Resa Farma | PHARMACEUTICAL COMPOSITIONS BASED ON DICLOFENAC |
NZ309841A (en) * | 1995-06-07 | 1999-10-28 | Quadrant Holdings Cambridge | Methods for producing foamed glass matrices (fgm) and compositions obtained thereby |
WO1996041646A2 (en) * | 1995-06-13 | 1996-12-27 | Dyer, Alison, Margaret | Pharmaceutical compositions containing lornoxicam and cyclodextrin |
IT1294205B1 (en) * | 1997-07-23 | 1999-03-24 | Farmigea Spa | PROCEDURE FOR THE SOLUBILIZATION IN WATER AND IN AQUEOUS VEHICLES OF PHARMACOLOGICALLY ACTIVE SUBSTANCES |
US8231899B2 (en) * | 1998-09-10 | 2012-07-31 | Nycomed Danmark Aps | Quick release pharmaceutical compositions of drug substances |
TR200100708T2 (en) | 1998-09-10 | 2001-07-23 | Nycomed Danmark A/S | Quick-release pharmaceutical compositions for pharmaceutical agents. |
ITMI20012749A1 (en) * | 2001-12-21 | 2003-06-21 | Chiesi Farma Spa | PROCEDURE FOR THE PREPARATION BY MICROWAVE TREATMENT OF INCLUSION COMPOUNDS BETWEEN DRUG AND CYCLODESTRINE AND PRODUCTS OBTAINED |
WO2004022100A1 (en) * | 2002-08-15 | 2004-03-18 | Yunqing Liu | Soild nano pharmaceutical formulation and preparation method thereof |
JO3352B1 (en) | 2005-06-17 | 2019-03-13 | Apr Applied Pharma Res Sa | Diclofenac formulations and methods of use |
CN101410123A (en) | 2006-03-28 | 2009-04-15 | 杰佛林制药公司 | Formulations of low dose diclofenac and beta-cyclodextrin |
EP2394641A1 (en) | 2010-05-30 | 2011-12-14 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of lornoxicam |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT52263B (en) * | 1911-04-22 | 1912-02-26 | Jean Baptiste Feilner | Process for making combination photographic negatives. |
HU176215B (en) * | 1978-01-27 | 1981-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1 |
JPS5920230A (en) * | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | Drug containing piruprophen |
DE3346123A1 (en) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF |
YU43290B (en) * | 1986-11-13 | 1989-06-30 | Lek Tovarna Farmacevtskih | Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine |
GB8813682D0 (en) * | 1988-06-09 | 1988-07-13 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
FR2647343B1 (en) * | 1989-05-24 | 1994-05-06 | Rhone Poulenc Sante | NOVEL POROUS PHARMACEUTICAL FORM AND ITS PREPARATION |
EP0491812A4 (en) * | 1989-09-14 | 1992-11-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
FR2660195B1 (en) * | 1990-03-28 | 1994-10-07 | Crinex Sa Laboratoires | PHARMACEUTICAL CHEWING, ANTI-INFLAMMATORY AND / OR ANALGESIC COMPOSITION. |
EP0519428B1 (en) * | 1991-06-21 | 2000-09-20 | Takeda Chemical Industries, Ltd. | Cyclodextrin compositions with fumagillol derivates |
GB9207990D0 (en) * | 1992-04-10 | 1992-05-27 | Smithkline Beecham Plc | Pharmaceutical composition |
-
1995
- 1995-05-22 JP JP8500478A patent/JPH10500982A/en active Pending
- 1995-05-22 AU AU25312/95A patent/AU2531295A/en not_active Abandoned
- 1995-05-22 WO PCT/GB1995/001152 patent/WO1995032737A1/en not_active Application Discontinuation
- 1995-05-22 BR BR9507768A patent/BR9507768A/en not_active Application Discontinuation
- 1995-05-22 EP EP95919524A patent/EP0760680A1/en not_active Withdrawn
- 1995-05-22 CA CA002190598A patent/CA2190598A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2190598A1 (en) | 1995-12-07 |
EP0760680A1 (en) | 1997-03-12 |
JPH10500982A (en) | 1998-01-27 |
BR9507768A (en) | 1997-09-02 |
WO1995032737A1 (en) | 1995-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AUPN411195A0 (en) | Medicinal composition | |
AU5136998A (en) | Medicinal composition | |
AU4762797A (en) | Pharmaceutical compositions | |
AU6740298A (en) | Pharmaceutical composition | |
AU2967597A (en) | Pharmaceutical compositions | |
AU7590096A (en) | Drug composition | |
AU3777897A (en) | Pharmaceutical compositions | |
AU5155096A (en) | Pharmaceutical composition | |
AU2531295A (en) | Pharmaceutical composition | |
AU5274096A (en) | Pharmaceutical compositions | |
AU9343098A (en) | Pharmaceutical composition | |
AU1475595A (en) | Pharmaceutical preparation | |
AU4326197A (en) | Pharmaceutical compositions | |
AUPN862596A0 (en) | Pharmaceutical compositions | |
AU4457597A (en) | Pharmaceutical compositions | |
AU1544195A (en) | Pharmaceutical compositions | |
AU1427895A (en) | Pharmaceutical compositions | |
AU6814496A (en) | Pharmaceutical composition | |
AUPN007494A0 (en) | Pharmaceutical composition | |
AUPM841894A0 (en) | Pharmaceutical composition | |
AUPM341094A0 (en) | Pharmaceutical composition | |
AU741226C (en) | Pharmaceutical composition | |
AU723097C (en) | Pharmaceutical composition | |
AUPM675994A0 (en) | Medicinal composition | |
AUPN890796A0 (en) | Pharmaceutical composition |